Teva told to divest assets by US Federal Trade Commission
Teva Pharmaceuticals has been told to sell certain rights and assets if the US Federal Trade Commission is to clear its $6.8bn acquisition of Cephalon.
Teva Pharmaceuticals has been told to sell certain rights and assets if the US Federal Trade Commission is to clear its $6.8bn acquisition of Cephalon.
The assets include selling all rights related to the company’s generic version of Actiq and muscle relaxant Amrix to US-based Par Pharmaceuticals.
Teva must also grant an undisclosed company non-exclusive US rights to market a generic version of Cephalon’s Provigil medication, used to treat sleep disorders.
All divestitures must be completed within ten days of the closing of Teva’s acquisition which, subject to EU approval, is due within the next week.
Sign up for our daily news round-up!
Give your business an edge with our leading industry insights.
Nominations are now closed for the Pharmaceutical Technology Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.
Excellence in Action Awarded the 2025 Pharmaceutical Technology Excellence Award for Business Expansion in Integrated Manufacturing, Upperton Pharma Solutions is rapidly expanding its UK GMP and sterile manufacturing footprint. Find out how Upperton’s integrated CDMO model helps pharma companies move from early development to clinical and niche commercial supply with fewer handovers and faster timelines.
